Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement

Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement Shashank Chaturvedi Department of Pharmaceutics, Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India. http://orcid.org/0000-0001-9151-694X Anurag Verma Department of Pharmaceutics, School of Pharmaceutical Sciences, IFTM University, Moradabad, Uttar Pradesh, India. http://orcid.org/0000-0002-2460-9967 Vikas Anand Saharan Department of Pharmaceutics, School of Pharmaceutical Sciences and Technology, Sardar Bhagwan Singh University, Dehradun, Uttarakhand, India. http://orcid.org/0000-0002-1353-6256

In the treatment of cancer, chemotherapy plays an important role though the efficacy of anticancer drug administered orally is limited, due to their poor solubility in physiological medium, inability to cross biological membrane, high Para-glycoprotein (P-gp) mediated drug efflux, and pre-systemic metabolism. These all factors cumulatively reduce drug exposure at the target site leading to multidrug resistance (MDR). Lipid based carriers systems has been explored to overcome solubility and permeability related issues of anti-cancer drugs. The lipid based formulations have also been reported to circumvent the effect of P-gp and CYP3A4. Further long chain triglycerides (LCT) has shown their ability to access Lymphatic route over Medium Chain Triglycerides, as the former has been extensively used for targeting anti-cancer drugs at proliferating cells through lymphatic route. Therefore this review tries to reflect the usefulness of lipid based drug carriers systems (viz. liposome, solid lipid nanoparticle, nano-lipid carriers, self-emulsifying, lipidic pro-drugs) in targeting lymphatic system and overcoming issues related to solubility and permeability of anti-cancer drugs. Moreover, we have also tried to reflect how critically lipid based carriers are important in maximizing therapeutic safety and efficacy of anti-cancer drugs.
08 09 2020 524 541 1 10.34172/crossmark_policy apb.tbzmed.ac.ir false Tabriz University of Medical Sciences Tabriz University of Medical Sciences 10.34172/apb.2020.064 20200812112350 https://apb.tbzmed.ac.ir/Article/apb-27971 https://apb.tbzmed.ac.ir/PDF/apb-10-524.pdf https://apb.tbzmed.ac.ir/PDF/apb-10-524.pdf https://apb.tbzmed.ac.ir/PDF/apb-10-524.pdf https://apb.tbzmed.ac.ir/PDF/apb-10-524.pdf https://apb.tbzmed.ac.ir/PDF/apb-10-524.pdf